Dantrium

Malignant Hyperthermia, Muscle Spasticity, Malignant Hyperthermia + 4 more
Treatment
20 Active Studies for Dantrium

What is Dantrium

DantroleneThe Generic name of this drug
Treatment SummaryDantrolene is a drug that does not act like other similar drugs, such as phenytoin, to treat seizures. It is a chemical derivative of hydantoin.
Dantrolene Sodiumis the brand name
image of different drug pills on a surface
Dantrium Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Dantrolene Sodium
Dantrolene
2005
36

Effectiveness

How Dantrium Affects PatientsDantrolene is a muscle relaxant and is the only effective treatment for malignant hyperthermia. It works by blocking the contractility of the muscle beyond the myoneural junction and by stopping the release of calcium from the sarcoplasmic reticulum. In those with malignant hyperthermia, certain triggering agents (e.g anesthetic drugs) can cause an increase in myoplasmic calcium which leads to a malignant hyperthermia crisis. Dantrolene helps to restore the normal level of calcium in the myoplasm, thus reducing the risk of a crisis.
How Dantrium works in the bodyDantrolene works by reducing the amount of calcium available to cause muscle contractions. It does this by attaching to the muscle's ryanodine receptors, which are responsible for releasing calcium from the sarcoplasmic reticulum.

When to interrupt dosage

The measure of Dantrium is contingent upon the recognized affliction, including Stroke, Spasticity and Spinal Cord Injury. The amount of dosage alters, in line with the mode of delivery (e.g. Capsule - Oral or Injection, solution - Intravenous) featured in the table beneath.
Condition
Dosage
Administration
Malignant Hyperthermia
, 25.0 mg, 50.0 mg, 100.0 mg, 2.0 mg/mL, 250.0 mg/mL, 20.0 mg
, Oral, Capsule, Capsule - Oral, Intravenous, Injection, Injection - Intravenous, Injection, suspension, Injection, suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, solution, Injection, solution - Intravenous
Malignant Hyperthermia
, 25.0 mg, 50.0 mg, 100.0 mg, 2.0 mg/mL, 250.0 mg/mL, 20.0 mg
, Oral, Capsule, Capsule - Oral, Intravenous, Injection, Injection - Intravenous, Injection, suspension, Injection, suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, solution, Injection, solution - Intravenous
Multiple Sclerosis
, 25.0 mg, 50.0 mg, 100.0 mg, 2.0 mg/mL, 250.0 mg/mL, 20.0 mg
, Oral, Capsule, Capsule - Oral, Intravenous, Injection, Injection - Intravenous, Injection, suspension, Injection, suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, solution, Injection, solution - Intravenous
Stroke
, 25.0 mg, 50.0 mg, 100.0 mg, 2.0 mg/mL, 250.0 mg/mL, 20.0 mg
, Oral, Capsule, Capsule - Oral, Intravenous, Injection, Injection - Intravenous, Injection, suspension, Injection, suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, solution, Injection, solution - Intravenous
Spinal Cord Injury
, 25.0 mg, 50.0 mg, 100.0 mg, 2.0 mg/mL, 250.0 mg/mL, 20.0 mg
, Oral, Capsule, Capsule - Oral, Intravenous, Injection, Injection - Intravenous, Injection, suspension, Injection, suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, solution, Injection, solution - Intravenous
Cerebral Palsy
, 25.0 mg, 50.0 mg, 100.0 mg, 2.0 mg/mL, 250.0 mg/mL, 20.0 mg
, Oral, Capsule, Capsule - Oral, Intravenous, Injection, Injection - Intravenous, Injection, suspension, Injection, suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, solution, Injection, solution - Intravenous
Muscle Spasticity
, 25.0 mg, 50.0 mg, 100.0 mg, 2.0 mg/mL, 250.0 mg/mL, 20.0 mg
, Oral, Capsule, Capsule - Oral, Intravenous, Injection, Injection - Intravenous, Injection, suspension, Injection, suspension - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, solution, Injection, solution - Intravenous

Warnings

Dantrium Contraindications
Condition
Risk Level
Notes
Muscle Spasticity
Do Not Combine
Muscle Spasticity
Do Not Combine
Cirrhosis
Do Not Combine
Hepatitis
Do Not Combine
Locomotion
Do Not Combine
Liver Diseases
Do Not Combine
There are 20 known major drug interactions with Dantrium.
Common Dantrium Drug Interactions
Drug Name
Risk Level
Description
Agmatine
Major
The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Agmatine.
Amiodarone
Major
The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Amiodarone.
Amlodipine
Major
The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Amlodipine.
Aranidipine
Major
The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Aranidipine.
Azelastine
Major
Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Dantrium Toxicity & Overdose RiskThe lowest toxic dose of the drug in rats has been found to be 7400mg/kg. Overdosing on the drug can lead to muscle weakness, altered consciousness (such as feeling drowsy or going into a coma), vomiting, diarrhea, and having crystals in the urine.
image of a doctor in a lab doing drug, clinical research

Dantrium Novel Uses: Which Conditions Have a Clinical Trial Featuring Dantrium?

258 active investigations are currently assessing the potential of Dantrium to improve Multiple Sclerosis, Spinal Cord Injury and Spasticity symptoms.
Condition
Clinical Trials
Trial Phases
Muscle Spasticity
0 Actively Recruiting
Multiple Sclerosis
127 Actively Recruiting
Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1
Malignant Hyperthermia
0 Actively Recruiting
Malignant Hyperthermia
0 Actively Recruiting
Cerebral Palsy
0 Actively Recruiting
Stroke
6 Actively Recruiting
Not Applicable, Phase 1
Spinal Cord Injury
67 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 1

Dantrium Reviews: What are patients saying about Dantrium?

5Patient Review
3/20/2012
Dantrium for Muscle Spasms caused by a Spinal Disease
I've been taking Dantrium for over 40 years and it's really helped with my muscle spasticity. I also take Valium, but neither of them have ever given me any negative side effects.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about dantrium

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of dantrolene?

"The following effects may occur as your body adjusts to the medication: drowsiness, dizziness, weakness, tiredness, nausea, and diarrhea. These effects usually lessen after several days. Headache, constipation, trouble speaking, and drooling may also occur. If you experience any of these effects for an extended period of time, or if they worsen, notify your doctor or pharmacist."

Answered by AI

What class of drug is Dantrium?

"Dantrium is a type of drug known as a Skeletal Muscle Relaxant."

Answered by AI

What is Dantrium IV?

"Dantrium Intravenous (dantrolene sodium) is mainly used as an emergency treatment for malignant hyperthermia, which is a rare reaction to medications (mainly anesthetics). Dantrium Intravenous is available in generic form."

Answered by AI

What is the medication Dantrium used for?

"The medication is used to treat muscle tightness and cramping caused by certain nerve disorders such as spinal cord injury, stroke, cerebral palsy, and multiple sclerosis. It relaxes the muscles."

Answered by AI

Clinical Trials for Dantrium

Image of Jacobs School of Medicine and Biomedical Sciences, Neurology, University at Buffalo in Buffalo, United States.

Mindset Training for MS

18 - 65
All Sexes
Buffalo, NY
People with Multiple Sclerosis (MS) often experience cognitive difficulties such as memory problems, concentration issues, and reduced processing speed. These symptoms can have a negative impact on daily functioning and overall quality of life. Previous research on cognitive rehabilitation has shown that regular training focused on memory and concentration can have positive effects on cognitive functioning, including processing speed, memory, and executive functions that support daily activities. Moreover, fMRI studies (brain scans that measure brain activity) have revealed changes in brain activation following cognitive rehabilitation. Recently, the idea has emerged that a more personalized approach could improve treatment outcomes. Specifically, researchers have identified a link between personality traits and cognitive functioning. Since every individual is different, current cognitive rehabilitation programs often fail to take these personal differences into account. In this project, the investigators aim to enhance the effectiveness of cognitive rehabilitation by focusing more closely on individual characteristics through an app-based training program. Participants will complete a 12-week app training prior to a 6-week cognitive rehabilitation program. The first app focuses on mindset training, supported by a coach. Afterwards, all participants will use a second app designed to train processing speed and memory. In addition to cognitive functioning, the investigators will also examine psychological, (neuro)biological, and social changes using questionnaires and fMRI. This research may provide valuable insights into how cognitive functioning and quality of life in people with MS can be improved. This study is funded by the National MS Fund and is a collaboration between several institutions: the Department of Health, Medical and Neuropsychology at Leiden University (The Netherlands), the University at Buffalo (USA), and Reha Rheinfelden (Switzerland).
Recruiting
New This Month
Jacobs School of Medicine and Biomedical Sciences, Neurology, University at BuffaloRalph HB Benedict, Prof
Have you considered Dantrium clinical trials? We made a collection of clinical trials featuring Dantrium, we think they might fit your search criteria.Go to Trials
Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Phase 1 & 2
Waitlist Available
Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)Gavin Solomon, President & CEOTruway Health, Inc.
Have you considered Dantrium clinical trials? We made a collection of clinical trials featuring Dantrium, we think they might fit your search criteria.Go to Trials
Image of Cognixion HQ in Santa Barbara, United States.

Cognixion + Apple Vision Pro for ALS

18+
All Sexes
Santa Barbara, CA
The goal of this study is refine the usability of a BCI capable communication platform. The study will take place in the United States area and will enroll up to 10 participants with late stage ALS, traumatic brain injury (TBI) or spinal cord injury (SCI) that have assistive communication and computer control needs. Each subject will receive an integrated Cognixion + Apple Vision Pro device that includes an augmented reality brain computer interface and associated communication software. The study duration is 3-4 months for each participant. The key questions that will be addressed in this study are: 1. Identify the ability of individuals with target indications to use the integrated Cognixion-Apple Vision Pro system to communicate effectively. 2. Identify the ability of such individuals to learn to use BCI, ET-BCI and other modalities, and to measure their progress over time. 3. Identify the effectiveness of the different forms of input supported by the combined Cognixion-Apple Vision Pro system (BCI, eye-tracking) in allowing such individuals to communicate and have agency. 4. Identify how input such as BCI can be optimized to suit the needs of individuals (e.g., specific frequencies that work best for an individual, SNR with different frequencies, number of targets, length of recording for each frequency) and improve overall usability. 5. Identify the extent to which personalization through a large language model (LLM) affects communication. 6. Identify the appropriate capabilities to enable through an agentic communication interface. Key measures include: ITR - information transfer rate SUS - system usability scale
Waitlist Available
Has No Placebo
Cognixion HQChristopher J UllrichCognixion
Image of John D. Dingell VA Medical Center in Detroit, United States.

Ocrelizumab for Multiple Sclerosis

18 - 75
All Sexes
Detroit, MI
This study seeks to assess the effects of long-term ocrelizumab therapy on fatigue (extreme tiredness) as well as cognition (thinking and reasoning skills, such as memory, learning and attention), in veterans with multiple sclerosis. The evaluation will involve cognitive assessment scales (to assess memory, attention and learning abilities), clinical evaluations (to assess nerve function and ability to move), and patient-reported outcome measures (in which you will answer questions about your tiredness, sleep and how you function in daily life). These assessments will occur at baseline (visit 1), 6 month (Visit-2) and 12 months (visit 3) to track changes over time.
Waitlist Available
Has No Placebo
John D. Dingell VA Medical CenterGenentech, Inc.
Image of Medical University of South Carolina in Charleston, United States.

Motor Evoked Potential Conditioning for Spinal Cord Injury

18+
All Sexes
Charleston, SC
The purpose of this research study is to examine the effect of a brain stimulation training to improve the function of brain-spinal cord- muscle connections. Because brain-to-muscle pathways are very important in our movement control, restoring function of these pathways may improve movement problems after injuries. Spinal cord injury causes damage to the brain-to-muscle connection. However, when the injury is "incomplete", there is a possibility that some of the brain-to-muscle pathways are still connected and may be trained to improve movement function. For examining brain-to-muscle pathways, investigators use a transcranial magnetic stimulator. Investigators hope that the results of this research study will help us develop new treatments for people who have movement disabilities. This study will require about 42 visits over the first 14 weeks, and another 6 visits over an additional 3 months. Each visit will take about 1 ½ hours.
Waitlist Available
Has No Placebo
Medical University of South CarolinaAiko Thompson, PhD
Have you considered Dantrium clinical trials? We made a collection of clinical trials featuring Dantrium, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security